Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A charity says a decision by the NHS in England to reject a drug for men with prostate cancer is a "fiasco".
Abiraterone is already given to patients at the end-of-life after chemotherapy as it gives patients an extra few months.
But the National Institute for Health and Care Excellence said it was not cost-effective to offer it earlier.
It said while the drug improved quality of life, it was unclear whether it had the same impact on life expectancy.
This was due to problems with the research data, NICE said, claiming the trial was finished early - something disputed by the drug's makers Janssen.
http://www.bbc.co.uk/news/health-28785250
Abiraterone is already given to patients at the end-of-life after chemotherapy as it gives patients an extra few months.
But the National Institute for Health and Care Excellence said it was not cost-effective to offer it earlier.
It said while the drug improved quality of life, it was unclear whether it had the same impact on life expectancy.
This was due to problems with the research data, NICE said, claiming the trial was finished early - something disputed by the drug's makers Janssen.
http://www.bbc.co.uk/news/health-28785250